Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.
Analysts from Bank of America Securities and Stifel Nicolaus reiterated their "Buy" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.
Additionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.